Sequential 5-Aza-2′-deoxycytidine-Depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1

Journal of Immunotherapy

Volumn 24, Issue 2, 2001, Pages 151-161

  Weiser, T S ^a   Sheng Guo, Z ^a   Ohnmacht, G A ^a   Parkhurst, M L ^a   Tong On, P ^a   Marincola, F M ^a   Fischette, M R ^a   Yu, X ^a   Chen, G A ^a   Hong, J A ^a   Stewart, J H ^a   Nguyen, D M ^a   Rosenberg, S A ^a   Schrump, D S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

5 Aza 2 deoxycytidine; Apoptosis; Depsipeptide FR901228; Esophageal cancer; Gene induction; Lung cancer; Malignant pleural mesothelioma; Melanoma; NY ESO 1; Tumor immunology

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTIGEN NY ESO1; ANTINEOPLASTIC AGENT; FR 901228; HISTONE DEACETYLASE INHIBITOR; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN SPECIFICITY; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; TESTIS CANCER; TUMOR SUPPRESSOR GENE;

ANTI-BACTERIAL AGENTS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIGENS, NEOPLASM; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DEPSIPEPTIDES; ESOPHAGEAL NEOPLASMS; FLOW CYTOMETRY; HUMANS; LUNG NEOPLASMS; MELANOMA; MEMBRANE PROTEINS; MESOTHELIOMA; NEOPLASMS; PEPTIDES, CYCLIC; PLEURAL NEOPLASMS; PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0035126974     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-200103000-00010     Document Type: Article

References (58)

1. Combined modality therapy of non-small cell lung cancers
2. Carcinoma of the esophagus. Part 1: Primary therapy
3. Mesothelioma: New concepts in diagnosis and management
4. CTL-defined cancer vaccines: Perspectives for active immunotherapeutic interventions in minimal residual disease
5. Cancer-testis antigens: Targets for cancer immunotherapy
6. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening
7. T cell defined tumor antigens
8. Serological identification of human tumor antigens
9. NY-ESO-1 may be a potential target for lung cancer immunotherapy
10. Expression of cancer-testis antigens in lung cancer: Definition of bromodomain testis-specific gene (BRDT) as a new CT gene, CT9
11. Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma
12. Humoral immune responses of cancer patients against 'cancer-testis' antigen NY-ESO-1: Correlation with clinical events
13. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens
14. Identification of human cancers deficient in antigen processing
15. Molecular basis for lack of expression of HLA class I antigens in human small-cell lung carcinoma cell lines
16. Escape of human solid tumors from T-cell recognition: Molecular mechanisms and functional significance
17. CpG methylation, chromatin structure and gene silencing-a three-way connection
18. Alterations in DNA methylation: A fundamental aspect of neoplasia
19. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns
20. The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation
21. NY-ESO-1 may be a potential target for lung cancer immunotherapy
22. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription
23. DNA methylation: Past, present and future directions
24. Epigenetic gene silencing in cancer
25. INK4 protein induction by 5-aza 2′ deoxycytidine
26. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer
27. Real time quantitative PCR
28. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor
29. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3
30. Evaluation of promoter strength for hepatic gene expression in vivo following adenovirus-mediated gene transfer
31. INK4
32. Quantification of cytokine mRNA expression by RT PCR in samples of previously frozen blood
33. Threshold levels of gene expression of the melanoma antigen gp 100 correlate with tumor cell recognition by cytotoxic T-lymphocytes
34. Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens
35. Antisense to SV40 early gene region induces growth arrest and apoptosis in T-antigen-positive human pleural mesothelioma cells
36. NY-ESO-1 tumour associated antigen is a cytoplasmic protein detectable by specific monoclonal antibodies in cell lines and clinical specimens
37. Simultaneous humoral and cellular immune response against cancer testis antigen NY-ESO-1: Definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes
38. Induction of tumor-reactive cytotoxic T-lymphocytes using a peptide from NY-ESO-1 modified at the carboxy-terminus to enhance HLA-A2.1 binding affinity and stability in solution
39. Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2)
40. Methylation, gene expression and the chromatin connection in cancer
41. Inactivation of the CDKN2/p16/NTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers
42. The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53
43. CpG island hypermethylation in human colorectal tumors is not associated with DNA methyltransferase overexpression
44. Cytidine analogues
45. Molecular, cellular and animal pharmacology of 5-Aza-2′-deoxycytidine
46. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal cell carcinoma
47. Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-Aza-2′-deoxycytidine
48. Lage-1, a new gene with tumor specificity
49. k) products on immunogenic variants of a spontaneous murine carcinoma
50. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium eviolaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity
51. Action of FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no. 968, on Ha-ras transformed NIH3T3 cells
52. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice
53. Induction of MAGE-3 expression in lung and esophageal cancer cells
54. Antigen capture, processing, and presentation by dendritic cells: Recent cell biological studies
55. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs
56. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers
57. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma
58. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1